Efficacy and safety of neural stem cell therapy for spinal cord injury: A systematic literature review

Tiwari, Santosh Kumar; Khan, Shaswati; Kumar, Shiva V.; Rajak, Rohit; Sultana, Asma; Pasha, Shaik A.; Gauba, Divya; Ghosh, Pranab; Khurana, Tanu; Kulkarni, Aishwarya; Reddy, Yugandhar P.; Khan, Aleem Ahmed; Sharma, Varun

doi:10.1016/j.therap.2020.06.011

Cited by 4 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides neuron replacement, neural stem cells can differentiate into glial cells, which play a vital role in the brain's immune response and may be affected by the FTD. The differentiation of the neurological stem cells into glial cells may reduce inflammation and promote restoration of brain function (142). Despite the promising results of animal studies, neural stem cell therapy is still experimental, and its efficacy and safety in human clinical trials are yet to be determined.…”

Section: Neural Stem Cell Therapy For Frontotemporal Dementiamentioning

confidence: 99%

Neural Stem Cell Therapies: Promising Treatments for Neurodegenerative Diseases

Gholamzad,

Sadeghi,

Azizabadi Farahani

et al. 2023

View full text Add to dashboard Cite

Neurodegenerative diseases are a group of disorders that progressively damage the nervous system, leading to loss of function and disability. Currently, there are limited treatment options available for patients suffering from these disorders. However, Neural Stem Cell Therapy is a promising new approach that has shown great potential in treating various neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis, spinocerebellar ataxia, frontotemporal dementia, Creutzfeldt-Jakob disease, and Lewy body disease. Through extensive research and clinical trials, Neural Stem Cell Therapy has been shown to reduce inflammation, enhance neuronal regeneration, and promote functional recovery in various neurological disorders. In Alzheimer's disease, Neural Stem Cell Therapy has been shown to improve cognitive function and reduce amyloid plaques. In Parkinson's disease, Neural Stem Cells have been shown to differentiate into dopaminergic neurons and improve motor function. In multiple sclerosis, Neural Stem Cells have been shown to remyelinate damaged axons and reduce inflammation.Although more research is still needed, the ongoing progress in this field holds significant implications for developing new treatment options for patients with neurodegenerative disorders. Neural Stem Cell Therapy has the potential to offer new hope to millions of individuals around the world who suffer from these debilitating diseases. As the field of Neural Stem Cell Therapy continues to evolve, it is hoped that this promising new approach will ultimately lead to better outcomes and improved quality of life for patients with neurodegenerative diseases.

show abstract

Section: Neural Stem Cell Therapy For Frontotemporal Dementiamentioning

confidence: 99%

Neural Stem Cell Therapies: Promising Treatments for Neurodegenerative Diseases

Gholamzad,

Sadeghi,

Azizabadi Farahani

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The low number of studies and small sample sizes across the studies invariably limits the quality of evidence for safety and efficacy outcomes for NSC therapy on review. Whilst a limited number of phase I/IIa clinical trials currently exist, Tiwari et al ( 91 ) conclude the safety of NSC transplantation for SCI in humans in a systematic review. The conclusions from the systematic review largely indicate the safety and tolerability of NSC transplantation, albeit the lack of a quantitative assessment of adverse events and serious adverse events across the studies.…”

Section: Stem Cell Therapy As the Basis For Combinatorial Therapymentioning

confidence: 99%

“…Based on their potential advantages, NSCs have been tested in phase I/IIa clinical trials for SCI cell therapy, which have been identified in the literature and listed below:• Shin et al (87), n = 19 • Ghobrial et al (88), n = 5 • Curtis et al (89), n = 4 • Levi et al (90), n = 31The low number of studies and small sample sizes across the studies invariably limits the quality of evidence for safety and efficacy outcomes for NSC therapy on review. Whilst a limited number of phase I/IIa clinical trials currently exist, Tiwari et al(91) conclude the safety of NSC transplantation for SCI…”

mentioning

confidence: 99%

Electroactive Scaffolds to Improve Neural Stem Cell Therapy for Spinal Cord Injury

Mutepfa

Hardy

Adams

2022

Front. Med. Technol.

View full text Add to dashboard Cite

Spinal cord injury (SCI) is a serious condition caused by damage to the spinal cord through trauma or disease, often with permanent debilitating effects. Globally, the prevalence of SCI is estimated between 40 to 80 cases per million people per year. Patients with SCI can experience devastating health and socioeconomic consequences from paralysis, which is a loss of motor, sensory and autonomic nerve function below the level of the injury that often accompanies SCI. SCI carries a high mortality and increased risk of premature death due to secondary complications. The health, social and economic consequences of SCI are significant, and therefore elucidation of the complex molecular processes that occur in SCI and development of novel effective treatments is critical. Despite advances in medicine for the SCI patient such as surgery and anaesthesiology, imaging, rehabilitation and drug discovery, there have been no definitive findings toward complete functional neurologic recovery. However, the advent of neural stem cell therapy and the engineering of functionalized biomaterials to facilitate cell transplantation and promote regeneration of damaged spinal cord tissue presents a potential avenue to advance SCI research. This review will explore this emerging field and identify new lines of research.

show abstract

Safety of a Medicinal Product Based on Human Glial Progenitor Cells: A Pilot Study of Retrobulbar Administration in C57BL/6J Mice

Nebogatikov,

Salikhova,

Belousova

et al. 2024

Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo pr

View full text Add to dashboard Cite

INTRODUCTION. Stem cell therapy is a promising treatment method for various diseases and injuries, but its safety has yet to be determined. Therefore, studying the safety of administering a xenogeneic cell-based medicinal product (CBMP) into the retro-orbital venous sinus is essential for developing protocols for further studies of potential medicinal products for neurological conditions.AIM. The aim of the study was to determine the optimal dose of a CBMP derived from glial progenitor cells (GPCs) and to evaluate its safety during retrobulbar administration in C57BL/6J mice.MATERIALS AND METHODS. GPCs were derived from human induced pluripotent stem cells by stepwise differentiation and cultured in DMEM/F12 supplemented with epidermal growth factor and ciliary neurotrophic factor. Matrigel was used as a substrate. GPCs were injected into the retro-orbital venous sinus of male C57BL/6J mice under isoflurane anaesthesia once a week for two months. The study analysed changes in biochemical blood parameters and behaviour. The quantities of activated astrocytes and glial cells were determined by postmortem immunohistochemical staining.RESULTS. The administration of GPCs at a dose of 500×103 cells/mouse, which was selected using literature data, induced an increase in the plasma levels of ala nine aminotransferase and aspartate aminotransferase. This could indicate cell damage and the development of inflammatory reactions. At doses reduced to one-third the initial GPC concentration or lower, the biochemical blood parameters of the treatment groups did not differ significantly from those of the control group. There were no significant differences in neuroinflammatory markers between the groups receiving GPCs at different doses, except for an increase in astrocyte activation at a dose of 150×103 cells/mouse, which could potentially indicate inflammatory processes in the brain. The study detected no pathological changes in the brain or cell damage markers in the blood of mice after retrobulbar GPC injections of 15×103 or 50×103 cells/mouse.CONCLUSIONS. The study results indicate that long-term therapy with GPCs is potentially safe for mice if the dose is optimal. The authors suggest using the optimal doses and the administration route established in this study for further research into the safety of intravenous administration of CBMPs for neurological conditions.

show abstract

Efficacy and safety of neural stem cell therapy for spinal cord injury: A systematic literature review

Cited by 4 publications

References 27 publications

Neural Stem Cell Therapies: Promising Treatments for Neurodegenerative Diseases

Neural Stem Cell Therapies: Promising Treatments for Neurodegenerative Diseases

Electroactive Scaffolds to Improve Neural Stem Cell Therapy for Spinal Cord Injury

Safety of a Medicinal Product Based on Human Glial Progenitor Cells: A Pilot Study of Retrobulbar Administration in C57BL/6J Mice

Contact Info

Product

Resources

About